15 results on '"Yuan, Zhongyu"'
Search Results
2. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
3. A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.
4. Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).
5. Efficacy and safety of pegfilgrastim in prophylaxis of chemotherapy-induced neutropenia in breast cancer patients.
6. Cost-effectiveness of primary prophylaxis with pegfilgrastim in early-stage breast cancer patients receiving chemotherapy in China.
7. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in Chinese population.
8. Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.
9. Two-year follow-up of pretreatment anti-mullerian hormone (AMH) to predict for resumption of mense after chemotherapy in premenopausal hormone-receptor (HR+) positive early breast cancer (eBC).
10. Fulvestrant as maintenance therapy after first-line chemotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer (FANCY), a prospective, multicenter, single arm phase 2 study.
11. Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment.
12. Endocrine treatment-related symptoms and outcomes in breast cancer: A systematic review and meta-analysis.
13. Fulvestrant as maintenance therapy after first-line chemotherapy in postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer patients (FANCY): A prospective, multicenter, single arm phase II study.
14. Prognosis and predictor role of PD-L1 expression in breast cancer patients between early recurrence and late recurrence.
15. Pretreatment anti-mullerian hormone to predict for resumption of mense in one year after chemotherapy in premenopausal hormone-receptor positive early breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.